Résultats de recherche - Portail des modèles médicaux de données (portail MDM)

Filtrer les résultats de recherche
Sélectionner modèles de données

Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

4 Résultats de recherche.

VISUAL FUNCTIONING QUESTIONNAIRE - 25 (DAY 0) CRFs Roche FVF4170G Macular Edema NCT-Nummer: NCT00473382

- 27/07/2017 - 1 Formulaire, 2 Groupes Item, 39 Eléments de données, 2 Langues

Groupes Item: Patient administration, VISUAL FUNCTIONING QUESTIONNAIRE - 25 (DAY 0)

Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4170g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

VISUAL FUNCTIONING QUESTIONNAIRE - 25 (DAY 0) CRFs Roche FVF4168G Macular Edema NCT00473330

- 27/07/2017 - 1 Formulaire, 2 Groupes Item, 39 Eléments de données, 2 Langues

Groupes Item: Patient administration, VISUAL FUNCTIONING QUESTIONNAIRE - 25 (DAY 0)

Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

RetDQoL (DAY 0) CRFs Roche FVF4170G Macular Edema NCT00473382

- 09/06/2017 - 1 Formulaire, 2 Groupes Item, 3 Eléments de données, 1 Langue

Groupes Item: Patient administration, RetDQoL (DAY 0)

Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4170g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

RetDQoL (DAY 0) CRFs Roche FVF4168G Macular Edema NCT00473330

- 08/06/2017 - 1 Formulaire, 2 Groupes Item, 3 Eléments de données, 1 Langue

Groupes Item: Patient administration, RetDQoL (DAY 0)

Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.